Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 83 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 83 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It has greater selectivity for vascular smooth muscle than for cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. It does not significantly affect sinoatrial nodal or atrioventricular conduction.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Administer intravenously at an initial rate of 5 mg/h, titrated by increasing by 2.5 mg/h every 5-15 minutes to a maximum of 15 mg/h for hypertension. For substitution of oral therapy, start at 0.5 mg/h and titrate to achieve desired blood pressure.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life is 8.6 hours (range 6-10 hours) in adults with normal hepatic function; prolonged in elderly or hepatic impairment. Clinical context: permits continuous IV infusion for stable hemodynamic control.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily hepatic metabolism (>90%) with <1% unchanged drug excreted renally. Fecal excretion accounts for approximately 35% of metabolites via biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte